Under clinical review. This page shows regulatory research prepared by Scriptura and is under active review by Sabrina Runbeck, PA-C, Clinical Director. Content may change on sign-off.
Peptide rules
Peptide rules by compound and jurisdiction
Scriptura reviews United States regulatory status for select peptides. Each compound page carries a named clinician sign-off and a review date. Every jurisdiction row shows the review status on that date and the plain public sources that informed it.
This is decision support for prescribing clinicians. It is not legal advice, not FDA guidance, and not a device.
Scriptura flags, alerts, and informs. The prescribing clinician makes every decision.
Compounds covered today
3 compounds shown here. Additional clinician reviewed compounds are covered in the private clinician tool. Sabrina Runbeck decides which compounds move to public review.
- CJC-1295 No-DACSigned by Sabrina Runbeck, PA-C, MPH, Clinical Advisor, Scriptura Health, on 2026-07-22.
- IpamorelinSigned by Sabrina Runbeck, PA-C, MPH, Clinical Advisor, Scriptura Health, on 2026-07-22.
- TesamorelinSigned by Sabrina Runbeck, PA-C, MPH, Clinical Advisor, Scriptura Health, on 2026-07-22.